In this issue of Blood, using induced pluripotent stem cell (iPSC)–derived human megakaryocytes (iMegs), Vo et al find that the megakaryocyte/platelet defects observed in patients with Paris-Trousseau syndrome (PTS) are… Click to show full abstract
In this issue of Blood, using induced pluripotent stem cell (iPSC)–derived human megakaryocytes (iMegs), Vo et al find that the megakaryocyte/platelet defects observed in patients with Paris-Trousseau syndrome (PTS) are due solely to hemizygous deletion of the transcription factor (TF) FLI1.1
               
Click one of the above tabs to view related content.